Tjitska Theadora “Thea” Kranzo, 56, of Jamestown, peacefully passed on surrounded by her beloved family and dogs at home on Friday, February 7, 2025. She was born to Gonnie Konneman Siekmans and the ...

The new Marius Pharmaceuticals website offers valuable resources on testosterone deficiency as a widespread health concern, emphasizing its impact beyond traditional perceptions. Recognizing the broad ...

Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the ...

Royalty Pharma (RPRX) announced that it has entered into an agreement with Biogen (BIIB) to provide research and development funding of up to $250M for litifilimab, a first-in-class ...

BERLIN, February 17, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for the ...

The yearslong bankruptcy case could be coming to a close. Purdue Pharma’s owners in the Sackler family have agreed to a new $6.5 billion settlement to lawsuits over their role in the U.S. opioid ...

DOC Pharma strengthens its offerings with the acquisition of the Geopharma nutraceuticals portfolio, and the closing of the previously announced acquisition of Muscoril® New brand identity ...

Our vision for our lead asset NOX-A12 remains clear: to secure approval for its use in glioblastoma patients through a strategic partnership with a pharmaceutical company, supported by ...

MILAN, Feb. 12, 2025 /PRNewswire/ -- DOC, an Italian pharmaceutical company specialized in the marketing of generic drugs, expands its strategy by broadening its business lines and defines a new ...

A new $7.4 billion settlement with states has been reached with Purdue Pharma and its Sackler family owners. We'll unpack. Most of the money from a newly-reached settlement over the fallout of the ...

Nvidia exited its positions in several AI stocks in Q4, but maintained its stake in Recursion Pharmaceuticals. Many investors seemed to view this as a vote of confidence from Nvidia for Recursion.